Table 3.
Comparative multivariate survival analysis of UTUC patients receiving NU.
| Multivariable analysis | OS | CSS | DFS | BRFS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Group | 0.672 | 0.770 | 0.489 | 0.170 | ||||
| LND (-) | 1 | 1 | 1 | 1 | ||||
| LND (+) | 1.086 (0.742, 1.588) | 1.069 (0.684, 1.671) | 0.889 (0.637, 1.241) | 1.272 (0.902, 1.793) | ||||
| Age | 0.016* | 0.309 | 0.483 | 0.446 | ||||
| <70 | 1 | 1 | 1 | 1 | ||||
| >=70 | 1.552 (1.084, 2.221) | 1.244 (0.817, 1.894) | 1.116 (0.822, 1.515) | 1.129 (0.827, 1.541) | ||||
| Histological variant | 0.434 | 0.792 | 0.307 | 0.855 | ||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 1.201 (0.759, 1.899) | 1.077 (0.621, 1.866) | 1.238 (0.822, 1.863) | 0.955 (0.582, 1.568) | ||||
| ECOG scores | 0.001** | 0.047* | 0.237 | 0.642 | ||||
| 0~1 | 1 | 1 | 1 | 1 | ||||
| 2~4 | 2.061 (1.363, 3.117) | 1.676 (1.008, 2.788) | 1.287 (0.847, 1.957) | 0.886 (0.532, 1.476) | ||||
| Multiplicity | 0.256 | 0.202 | 0.239 | 0.030* | ||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 1.232 (0.859, 1.767) | 1.318 (0.863, 2.014) | 1.208 (0.882, 1.655) | 1.446 (1.035, 2.020) | ||||
| History of BC | ||||||||
| No | 1 | 1 | 1 | 1 | ||||
| Previous BC | 2.502 (1.294, 4.838) | 0.006* | 2.887 (1.323, 6.301) | 0.008* | 1.650 (0.869, 3.133) | 0.126 | 2.829 (1.602, 4.997) | <0.001** |
| Concurrent BC | 1.523 (0.953, 2.434) | 0.079 | 1.865 (1.105, 3.147) | 0.020* | 1.952 (1.317, 2.892) | 0.001** | 1.581 (1.022, 2.446) | 0.040* |
| Preoperative hydronephrosis | < 0.001** | < 0.001** | 0.011* | 0.457 | ||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 2.617 (1.697, 4.035) | 2.522 (1.518, 4.191) | 1.526 (1.100, 2.116) | 1.132 (0.816, 1.571) | ||||
| Lymphovascular invasion | 0.136 | 0.035 | < 0.001** | 0.449 | ||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 1.317 (0.917, 1.891) | 1.565 (1.032, 2.374) | 1.744 (1.289, 2.361) | 0.872 (0.611, 1.244) | ||||
| Tumor grade | 0.161 | 0.023* | 0.026* | |||||
| Low grade | 1 | 1 | 1 | |||||
| High grade | 1.921 (0.771, 4.784) | 2.846 (1.158, 6.995) | 0.589 (0.369, 0.938) | |||||
| pathological stage T | ||||||||
| pT2 | 1 | 1 | 1 | 1 | ||||
| pT3 | 1.530 (1.043, 2.244) | 0.030* | 1.859 (1.151, 3.002) | 0.011* | 1.737 (1.236, 2.440) | 0.001** | 0.875 (0.636, 1.203) | 0.410 |
| pT4 | 3.939 (1.985, 7.817) | <0.001** | 5.038 (2.307, 11.000) | <0.001** | 3.252 (1.770, 5.975) | <0.001** | 0.127 (0.017, 0.928) | 0.042* |
Cl, confidence; HR, hazard ratio; OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; BRFS, Bladder Recurrence-free survival.
* < 0.05, ** < 0.01.